MY167891A - Methods for the synthesis and purification of deoxycholic acid - Google Patents

Methods for the synthesis and purification of deoxycholic acid

Info

Publication number
MY167891A
MY167891A MYPI2012002415A MYPI2012002415A MY167891A MY 167891 A MY167891 A MY 167891A MY PI2012002415 A MYPI2012002415 A MY PI2012002415A MY PI2012002415 A MYPI2012002415 A MY PI2012002415A MY 167891 A MY167891 A MY 167891A
Authority
MY
Malaysia
Prior art keywords
synthesis
deoxycholic acid
methods
purification
keto
Prior art date
Application number
MYPI2012002415A
Other languages
English (en)
Inventor
Robert M Moriarty
Achampeta Rathan Prasad
John Gregory Reid
Jr Roy A Swaringen
Original Assignee
Kythera Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kythera Biopharmaceuticals Inc filed Critical Kythera Biopharmaceuticals Inc
Publication of MY167891A publication Critical patent/MY167891A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2012002415A 2009-12-18 2010-12-17 Methods for the synthesis and purification of deoxycholic acid MY167891A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28813209P 2009-12-18 2009-12-18
US30200710P 2010-02-05 2010-02-05
US30381610P 2010-02-12 2010-02-12
GB1008726A GB2480632A (en) 2010-05-25 2010-05-25 Preparation of 12-keto and 12-alpha-hydroxy steroids
US34868610P 2010-05-26 2010-05-26

Publications (1)

Publication Number Publication Date
MY167891A true MY167891A (en) 2018-09-26

Family

ID=42341289

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012002415A MY167891A (en) 2009-12-18 2010-12-17 Methods for the synthesis and purification of deoxycholic acid

Country Status (17)

Country Link
US (5) US20130137884A1 (enExample)
EP (2) EP2513132B9 (enExample)
JP (2) JP6393023B2 (enExample)
KR (3) KR101862599B1 (enExample)
CN (3) CN102812035A (enExample)
AU (1) AU2010330760B2 (enExample)
CA (1) CA2782478A1 (enExample)
EA (2) EA035380B1 (enExample)
ES (1) ES2575559T3 (enExample)
GB (1) GB2480632A (enExample)
IL (2) IL220225A0 (enExample)
MY (1) MY167891A (enExample)
NZ (1) NZ700195A (enExample)
PH (1) PH12012501233A1 (enExample)
SG (3) SG10201803507YA (enExample)
WO (1) WO2011075701A2 (enExample)
ZA (1) ZA201204388B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
GB2480632A (en) 2010-05-25 2011-11-30 Kythera Biopharmaceuticals Inc Preparation of 12-keto and 12-alpha-hydroxy steroids
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
EP2721047B1 (en) * 2011-06-16 2016-11-16 Kythera Biopharmaceuticals, Inc. Methods for the synthesis and purification of deoxycholic acid
US20130102580A1 (en) * 2011-09-22 2013-04-25 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs
WO2013044119A1 (en) * 2011-09-22 2013-03-28 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs
CN104447929B (zh) * 2014-10-28 2016-06-29 湖南科瑞生物制药股份有限公司 一种合成3-羰基-4-雄烯-17β羧酸的方法
CN106146593B (zh) * 2015-04-14 2021-06-01 南京迈诺威医药科技有限公司 一种制备去氧胆酸的方法
CN106046093A (zh) * 2016-05-30 2016-10-26 华东师范大学 一种石胆酸的合成方法
US11117925B2 (en) 2016-06-06 2021-09-14 Bionice, S.L.U. Methods for the preparation of deoxycholic acid, and intermediates useful in the preparation of deoxycholic acid
US20190125648A1 (en) * 2016-08-11 2019-05-02 Samsung Life Public Welfare Foundation Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient
WO2019024920A1 (en) 2017-08-03 2019-02-07 Medytox Inc. PROCESSES FOR PREPARING BILARY ACIDS
JP6899529B2 (ja) 2017-08-10 2021-07-07 パナソニックIpマネジメント株式会社 冷凍サイクル用作動媒体および冷凍サイクルシステム
CN114478676B (zh) * 2022-02-18 2024-05-10 国药集团化学试剂有限公司 一种脱氧胆酸钠的制备方法
CN116444597B (zh) * 2023-03-30 2025-03-28 南京迈诺威医药科技有限公司 一种制备去氧胆酸中间体和去氧胆酸的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53446A (en) 1866-03-27 Improvement in cultivators
US2321598A (en) 1940-10-07 1943-06-15 George A Breon & Company Inc Preparation of desoxycholic acid
US2509248A (en) * 1947-09-05 1950-05-30 Merck & Co Inc Process for producing delta9, 11-3(alpha)-hydroxy-17-ketoetiocholene
GB695504A (en) 1950-10-18 1953-08-12 Drug Res Inc Method of isolating and purifying cholic and desoxycholic acids
US2651643A (en) * 1951-06-19 1953-09-08 Armour & Co Purification of desoxycholic acid
GB716670A (en) 1951-06-19 1954-10-13 Armour & Co Improved process for purifying desoxycholic acid from contaminating cholic acid
US2891972A (en) 1952-08-19 1959-06-23 Drug Res Inc Process of separating desoxycholic acid from mixed crude bile acids or salts thereof
US3533908A (en) 1967-05-19 1970-10-13 Brown Co Porous paperboard sheet having plastic microspheres therein
IT1202370B (it) 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
FR2446293A1 (fr) 1978-12-11 1980-08-08 Roussel Uclaf Procede de purification de l'acide chenodesoxycholique
IT8167097A0 (it) 1981-01-26 1981-01-26 Unilever Nv Composizione cosmetica per il trattamento della pelle o dei capelli
HU208437B (en) 1988-04-08 1993-10-28 Roussel Uclaf Process for producing 9-alpha-hydroxy- -17-methylene-steroides for synthetizing corticosteroides
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
WO1996003127A1 (en) 1994-07-25 1996-02-08 Nda International, Inc. A method of treating chemical dependency in mammals and a composition therefor
US20020107291A1 (en) 1997-05-26 2002-08-08 Vincenzo De Tommaso Clear, injectable formulation of an anesthetic compound
IL123998A (en) 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
US6417179B1 (en) 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
WO2000047215A2 (en) * 1999-02-12 2000-08-17 Cellpath, Inc. Methods for anti-tumor therapy
CN100558407C (zh) 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
US6696580B2 (en) 2001-05-22 2004-02-24 Inflazyme Pharmaceuticals Ltd. Process for the production of 6,7-diols of steroidal compounds
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US20060222695A1 (en) 2005-04-01 2006-10-05 Filiberto Zadini Deoxycholic acid liposome-based dermatological topical preparation
CN101148468A (zh) 2006-09-19 2008-03-26 天津科技大学 以动物胆汁为原料高效提取胆红素和胆汁酸技术
CA2928178C (en) * 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) * 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
DK2407475T3 (en) * 2007-06-19 2015-10-26 Kythera Biopharmaceuticals Inc Preparation of synthetic bile acid
DK2300489T3 (en) * 2008-06-06 2016-02-15 Neurmedix Inc PROCESSES FOR PREPARING 17-alkynyl-7-HYDROXY STEROIDS AND RELATED COMPOUNDS
GB2480632A (en) 2010-05-25 2011-11-30 Kythera Biopharmaceuticals Inc Preparation of 12-keto and 12-alpha-hydroxy steroids
EP2721047B1 (en) 2011-06-16 2016-11-16 Kythera Biopharmaceuticals, Inc. Methods for the synthesis and purification of deoxycholic acid
US20130102580A1 (en) 2011-09-22 2013-04-25 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs

Also Published As

Publication number Publication date
US10005813B2 (en) 2018-06-26
US10981946B2 (en) 2021-04-20
SG10201803507YA (en) 2018-05-30
AU2010330760B2 (en) 2015-01-22
EP3040342A1 (en) 2016-07-06
GB201008726D0 (en) 2010-07-07
EA201290334A1 (ru) 2013-06-28
NZ700195A (en) 2016-03-31
KR20120107982A (ko) 2012-10-04
PH12012501233A1 (en) 2012-11-05
CN106955287A (zh) 2017-07-18
US10472384B2 (en) 2019-11-12
JP6568025B2 (ja) 2019-08-28
KR102058420B1 (ko) 2019-12-24
EA031768B1 (ru) 2019-02-28
US20190135855A1 (en) 2019-05-09
EA035380B1 (ru) 2020-06-04
CN102812035A (zh) 2012-12-05
AU2010330760A1 (en) 2012-06-21
EP2513132B9 (en) 2017-12-27
US20170320905A1 (en) 2017-11-09
EP2513132A2 (en) 2012-10-24
US9683007B2 (en) 2017-06-20
CN107011401A (zh) 2017-08-04
JP2013515006A (ja) 2013-05-02
KR101862599B1 (ko) 2018-05-31
KR101787719B1 (ko) 2017-10-18
IL261526A (en) 2018-10-31
CA2782478A1 (en) 2011-06-23
WO2011075701A4 (en) 2012-09-13
WO2011075701A2 (en) 2011-06-23
KR20180059568A (ko) 2018-06-04
JP6393023B2 (ja) 2018-09-19
KR20170049635A (ko) 2017-05-10
ES2575559T3 (es) 2016-06-29
SG181768A1 (en) 2012-07-30
EP2513132B1 (en) 2016-03-09
GB2480632A (en) 2011-11-30
ZA201204388B (en) 2013-07-31
US20200095274A1 (en) 2020-03-26
US20130137884A1 (en) 2013-05-30
JP2016193948A (ja) 2016-11-17
US20150141679A1 (en) 2015-05-21
IL220225A0 (en) 2012-07-31
WO2011075701A3 (en) 2012-07-26
SG10201509046TA (en) 2015-12-30
EA201791511A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
PH12012501233A1 (en) Methods for the purification of deoxycholic acid
SG176015A1 (en) Antiviral compounds
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
MX2009013830A (es) Compuestos antivirales.
MX2009013827A (es) Compuestos antivirales.
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
SG178920A1 (en) Novel polymorphs of rebaudioside c and methods for making and using the same
NZ605234A (en) Process for the synthesis of substituted morphinans
MX377644B (es) 6.7.beta-epóxidos esteroideos como intermedios químicos.
NZ606720A (en) A method of producing ingenol-3-angelate
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
WO2012029077A3 (en) Process for preparing fluticasone propionate/furoate
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX339361B (es) Derivados de alternano.
UA106988C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та необхідні проміжні сполуки магнію
BR112014006844A2 (pt) composições e métodos relacionados ao ácido deoxicólico e seus polimorfos
TW200734326A (en) Crystalline forms of dolasetron base and processes for preparation thereof
MX2010003056A (es) Polimorfos de valomaciclovir.
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2010122575A3 (en) Process for the preparation of pure paliperidone
WO2010059916A3 (en) Preparation of docetaxel
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.